Jacob Gottlieb and Stuart Weisbrod have been working together in the past under the Merlin BioMed Group, but they decided to separate and took on different career paths. But recently, a new development took place, and the two were reunited once again under the same roof. Stuart Weisbrod started working with Jacob Gottlieb back in 1998 when he co-founded Merlin BioMed Group. The company focused on health care and medical innovation, and Stuart Weisbrod contributed to the company’s success by making it one of the most successful medical firms in the United States. They also invested in other medical related ventures and made it possible for the Merlin BioMed Group to become more competitive when it comes to their performance. The two founders of the company managed to increase the profits of their investors, by making the company more valuable. However, in 2007, they decided to split, and all of the assets invested in the company were eventually returned to their investors.
Stuart Weisbrod created his investment firm, which is known as Iguana Healthcare Partners. Jacob Gottlieb also established his own company, named the Visium Asset Management. The two companies have focused on two different sectors, with the Iguana Healthcare Partners focusing on public healthcare firms, while Visium Asset Management is focusing on the financial sector. The $300 million capital invested by Jacob Gottlieb exponentially grew to over $2.5 billion. It later grew to an $8 billion business, employing more than 200 people. The economic recession in 2008 did not stop these companies from growing, partly because the founders knew about this scenario and they have already prepared themselves if a similar event happens,
In 2016, the Visium Asset Management had to close down its doors, but Jacob Gottlieb continued his stint in the financial world and established the Altium Capital along with Stuart Weisbrod. Altium Capital invested a 5.61% stake in Oramed Pharmaceuticals Inc., and it started their company’s transformation. Oramed Pharmaceuticals Inc. produces a treatment for diabetic patients, and the products that they are manufacturing are now under the review from the FDA. International researchers stated that the treatment they created for diabetic patients is highly effective.